Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe vision loss from retinal degenerative ...

Our eyes are one of the most important organs of our body, and not only are they our tool to see the outside world, but they can also be a reflection of our health. Changes in our eyes are not always ...

Regulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks ...

New study shows cheap HIV drug lamivudine helps diabetic macular edema, improving vision. Oral option could replace eye ...

Glaukos Q1 results beat expectations, and the company is delivering on a robust pipeline as it continues to build an ...

A recent study discovered that an inexpensive HIV drug could be effective for diabetic people by reversing a complication ...

Researchers have found in a phase 3 trial that phentolamine ophthalmic solution 0.75% led to significant improvements in ...

The drug, lamivudine, appears to improve vision that’s being threatened by diabetic macular edema (DME), an eye condition in ...

The global adaptive optics market revenue was around US$ 494.5 million in 2021 and is estimated to reach US$ 3846.5 billion by 2030, growing at a compound annual growth rate (CAGR) of 25.6% during the ...

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing ...

Aims To describe the relationship of retinal arteriolar and venular calibre with diabetic retinopathy (DR) and related risk factors, including glucose levels and other biomarkers in a Chinese ...

Patients with type 2 diabetes have a demonstrably higher than average risk of developing neurodegenerative conditions, particularly cognitive dysfunction such as Alzheimer's disease. 108 As the retina ...